This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Phase II results were presented at the American College of Cardiology 2025 Scientific Sessions. Lilly shared that the ACCLAIM-Lp(a) Phase III clinicaldevelopment program is currently enrolling. The findings suggest that lepodisiran could offer a durable treatment option for individuals with elevated Lp(a) levels.
We are taking bold steps into the future of drug development, investing strongly in areas at the forefront of the biomedical and technological revolution. Every year 47 million women enter menopause, a period where women are at the peak of their life’s activity, personally and professionally.
“Patients with Parkinson’s disease are faced with life changing challenges and uncertainties that are not addressed by current treatments,” said Ahmed Enayetallah, M.D., Senior Vice President, ClinicalDevelopment, BlueRock Therapeutics. “We For more information, visit www.bluerocktx.com.
Patient advocacy groups, including the Amyloidosis Support Groups led by Muriel Finkel, highlight the transformative impact of Attruby on the lives of those with ATTR-CM.
This is a part of the precision cardiology approach and could lead to their use as prognostic indicators. Full-Service ClinicalDevelopment. The Double-Edged Sword of Cardiac Biomarkers.
The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinicaldevelopment. About Bayer Bayer is a global enterprise with core competencies in the lifescience fields of health care and nutrition.
The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinicaldevelopment. About Bayer Bayer is a global enterprise with core competencies in the lifescience fields of health care and nutrition.
Accelerating Global Radiopharmaceutical ClinicalDevelopment To arrive at success in your radiopharmaceutical development, it takes a team-based approach to drive evidence-based clinical decisions. References The Green Journal. Radiotherapy and Oncology.
The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinicaldevelopment. About Bayer Bayer is a global enterprise with core competencies in the lifescience fields of health care and nutrition.
Jansen recently moderated a webinar in which her colleagues at Medpace discussed the evolving women’s health sector, including the historical challenges and emerging trends in clinicaldevelopment. Another example is heart disease, the leading cause of death for both men and women in the US. Health disparities add to these challenges.
With Blackstone LifeSciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinicaldevelopment programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma. billion ($19.19 billion USD), a 13.30
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content